表紙
市場調査レポート

筋萎縮性側索硬化症 - パイプライン分析

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232799
出版日 ページ情報 英文 504 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
筋萎縮性側索硬化症 - パイプライン分析 Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 504 Pages
概要

筋萎縮性側索硬化症(ALS) は運動ニューロン・システムの最も一般的な変性疾患です。この障害は、その原因となっている病態生理学から名づけられ、筋繊維の萎縮に関する筋萎縮症を伴い、対応する前角細胞が退化するに従い、神経が麻痺していきます。 この領域の上位運動ニューロン(UMN)軸索が変質して、繊維星状細胞(神経膠症)に取って代わるため、側索硬化症は脊髄の側柱で見られる変化に関係があります。 症候として、呼吸困難、嚥下障害、首の筋力低下で頭が前に垂れる、筋けいれん、遅いか異常な話し方(語を不明瞭に発音するなど)といった会話障害、変声、しゃがれ声、体重の減少などが見られます。

当レポートでは、筋萎縮性側索硬化症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 筋萎縮性側索硬化症 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7974IDB

Summary

Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2016', provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis
  • The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects
  • The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Amyotrophic Lateral Sclerosis Overview
  • Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies
  • Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes
  • Amyotrophic Lateral Sclerosis - Pipeline Products Glance
  • Amyotrophic Lateral Sclerosis - Products under Development by Companies
  • Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes
  • Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Therapeutics Assessment
  • Drug Profiles
  • Amyotrophic Lateral Sclerosis - Recent Pipeline Updates
  • Amyotrophic Lateral Sclerosis - Dormant Projects
  • Amyotrophic Lateral Sclerosis - Dormant Projects
  • Amyotrophic Lateral Sclerosis - Discontinued Products
  • Amyotrophic Lateral Sclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2016
  • Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Biogen, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Daval International Limited, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Gemac, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Genentech, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex S.A., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Grifols, S.A., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by IntelliCell BioSciences Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corporation, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica Plc, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed S.L., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Symic Biomedical, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Thera Neuropharma, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by UCB S.A., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by UniQure N.V., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by VivaCell Biotechnology Espana S.L., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics, Inc., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd., H1 2016
  • Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H1 2016
  • Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..9), H1 2016
  • Amyotrophic Lateral Sclerosis - Discontinued Products, H1 2016
  • Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2016
  • Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top